First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

• Status: Recruiting
• Trial end date: 2023-10-31
• Target enrollment: 0
• Participant gender: All

Summary

This is the first-in-human study of 68Ga/64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Collaborator: Sinotau Pharmaceutical Group

Criteria

Inclusion Criteria:

• 1. signed the informed consent

• 2. ≥18 years old

• 3. confirmed as malignant solid tumor by histopathology or clinical judgment

• 4. Patients will undergo 18F-FDG PET/CT examination

Exclusion Criteria:

• 1. Known allergy to components of the investigational drug or its analogues

• 2. suspected to have a certain disease or condition that is not suitable for the study drug

• 3. Known pregnant or lactating women